Evidence map›Paper›PMID 32412846›Full record

ArticleJCO clinical cancer informatics2020

Electronic Medical Record Search Engine (EMERSE): An Information Retrieval Tool for Supporting Cancer Research.

David A Hanauer, Jill S Barnholtz-Sloan, Mark F Beno, Guilherme Del Fiol, Eric B Durbin, Oksana Gologorskaya, Daniel Harris, Brett Harnett, Kensaku Kawamoto, Benjamin May and 4 more

Abstract read
In one paragraph

Article in JCO clinical cancer informatics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

David A HanauerDepartment of Pediatrics, University of Michigan Medical School, Ann Arbor, MI.
Jill S Barnholtz-SloanCase Western Reserve University School of Medicine, Cleveland, OH.
Mark F BenoCase Western Reserve University School of Medicine, Cleveland, OH.
Guilherme Del FiolDepartment of Biomedical Informatics, University of Utah, Salt Lake City, UT.
Eric B DurbinMarkey Cancer Center, UK HealthCare, Lexington, KY.
Oksana GologorskayaClinical and Translational Science Institute, University of California San Francisco, San Francisco, CA.
Daniel HarrisMarkey Cancer Center, UK HealthCare, Lexington, KY.
Brett HarnettDepartment of Biomedical Informatics, University of Cincinnati College of Medicine, Cincinnati, OH.
Kensaku KawamotoDepartment of Biomedical Informatics, University of Utah, Salt Lake City, UT.
Benjamin MayHerbert Irving Comprehensive Cancer Center, Columbia University, New York, NY.
Eric MeeksClinical and Translational Science Institute, University of California San Francisco, San Francisco, CA.
Emily PfaffNorth Carolina Translational and Clinical Sciences Institute, University of North Carolina School of Medicine, Chapel Hill, NC.
Janie WeissHerbert Irving Comprehensive Cancer Center, Columbia University, New York, NY.
Kai ZhengDepartment of Informatics, University of California, Irvine, CA.

Funding

Michigan Institute for Clinical and Health Research (MICHR)UL1TR002240 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUMENG, JULIE C, MASHOUR, GEORGE ALEXANDER · 2017 to 2022
$54.9M
Re-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6M
University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Jennifer F Rogers · 2013 to 2026
$38.3M
Clinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5M
University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
Advanced Development and Dissemination of EMERSE for Cancer Phenotyping from Medical RecordsU24CA204863 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HANAUER, DAVID ALAN · 2017 to 2021
$3.8M
NCATS NIH HHS UL1 TR001414NCATS NIH HHS UL1 TR002240NCATS NIH HHS UL1 TR002489NCATS NIH HHS UL1 TR002548NCI NIH HHS P30 CA177558NCI NIH HHS U24 CA204863
6 · The paper itself

Abstract

purposeThe Electronic Medical Record Search Engine (EMERSE) is a software tool built to aid research spanning cohort discovery, population health, and data abstraction for clinical trials. EMERSE is now live at three academic medical centers, with additional sites currently working on implementation. In this report, we describe how EMERSE has been used to support cancer research based on a variety of metrics.

methodsWe identified peer-reviewed publications that used EMERSE through online searches as well as through direct e-mails to users based on audit logs. These logs were also used to summarize use at each of the three sites. Search terms for two of the sites were characterized using the natural language processing tool MetaMap to determine to which semantic types the terms could be mapped.

resultsWe identified a total of 326 peer-reviewed publications that used EMERSE through August 2019, although this is likely an underestimation of the true total based on the use log analysis. Oncology-related research comprised nearly one third (n = 105; 32.2%) of all research output. The use logs showed that EMERSE had been used by multiple people at each site (nearly 3,500 across all three) who had collectively logged into the system > 100,000 times. Many user-entered search queries could not be mapped to a semantic type, but the most common semantic type for terms that did match was "disease or syndrome," followed by "pharmacologic substance."

conclusionEMERSE has been shown to be a valuable tool for supporting cancer research. It has been successfully deployed at other sites, despite some implementation challenges unique to each deployment environment.

Indexed as

NeoplasmsSearch EngineElectronic Health RecordsHumansInformation Storage and RetrievalNatural Language ProcessingSoftware

Identifiers

PMID32412846
PMCPMC7265780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.